A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
ITEM 1. BUSINESS Prothena Corporation plc (“Prothena” or the “Company”) is a late-stage clinical biotechnology company with expertise in protein dysregulation with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, the Company is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. The Company’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including Parkinson’s disease, ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, Amyotrophic lateral sclerosis (ALS) and a number of other neurodegenerative diseases.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | 135M | 91M | - | 201M |
| Net Income | -244M | -244M | -122M | -147M | -117M | 67M |
| EPS | $-4.53 | $-4.53 | $-2.27 | $-2.76 | $-2.47 | $1.38 |
| Free Cash Flow | -164M | -164M | -150M | -137M | -109M | 92M |
| ROIC | -51.9% | -63.6% | -25.1% | -26.2% | -18.8% | 14.4% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.03 | 0.03 | 0.02 | 0.02 | 0.01 | 0.03 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -215M | -215M | -155M | -191M | -132M | 72M |
| Operating Margin | 0.0% | - | -114.4% | -209.1% | - | 35.9% |
| ROE | -87.0% | -63.6% | -25.1% | -26.2% | -18.8% | 14.4% |
| Shares Outstanding | 54M | 54M | 54M | 53M | 47M | 49M |
PROTHENA CORP PUBLIC LTD CO passes 1 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is +6.3%.
PROTHENA CORP PUBLIC LTD CO (PRTA) has a 5-year average return on invested capital (ROIC) of -23.9%. This is below average and may indicate limited pricing power.
PROTHENA CORP PUBLIC LTD CO (PRTA) has a market capitalization of $572M. It is classified as a small-cap stock.
PROTHENA CORP PUBLIC LTD CO (PRTA) does not currently pay a regular dividend.
PROTHENA CORP PUBLIC LTD CO (PRTA) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
PROTHENA CORP PUBLIC LTD CO (PRTA) generated $-164 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
PROTHENA CORP PUBLIC LTD CO (PRTA) has a debt-to-equity ratio of 0.03. This indicates a conservatively financed balance sheet.
PROTHENA CORP PUBLIC LTD CO (PRTA) reported earnings per share (EPS) of $-4.53 in its most recent fiscal year.
PROTHENA CORP PUBLIC LTD CO (PRTA) has a return on equity (ROE) of -63.6%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 15 years of financial data for PROTHENA CORP PUBLIC LTD CO (PRTA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
PROTHENA CORP PUBLIC LTD CO (PRTA) has a book value per share of $5.21, based on its most recent annual SEC filing.
No recent press releases.